Oxymetholone: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
No edit summary
Line 1: Line 1:


{{DrugProjectFormSinglePage
|authorTag=<!--Overview-->
|aOrAn=a
|hasBlackBoxWarning=Yes
|adverseReactions=<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


{{Drugbox|
* Content
|IUPAC_name = 17β-hydroxy-2-hydroxymethylene-<br>17α-methyl-3-androstanone
 
| image= Oxymetholone.svg
<!--Adult Indications and Dosage-->
| CAS_number=434-07-1
 
| ATC_prefix=A14
<!--FDA-Labeled Indications and Dosage (Adult)-->
| ATC_suffix=AA05
|fdaLIADAdult======Condition1=====
| ATC_supplemental=
 
| PubChem=9902
* Dosing Information
| DrugBank=
 
| C= 21 | H= 32 | O= 3
:* Dosage
| molecular_weight = 332.48 g/mol
 
| bioavailability= 95%
=====Condition2=====
| metabolism = [[Liver|Hepatic]]
 
| elimination_half-life=8-9 hours
* Dosing Information
| excretion = [[Urine|Urinary]]:95%
 
| pregnancy_category = X
:* Dosage
| legal_status = Prescription only <br> ([[United States|US]])
 
| routes_of_administration= [[Mouth|Oral]]
=====Condition3=====
}}
 
{{SI}}
* Dosing Information
'''Oxymetholone''' ('''Anadrol'''), is a synthetic [[anabolic steroid]] developed by [[Syntex]] in 1960. Its primary clinical applications include treatment of [[osteoporosis]] and [[anaemia]], as well as stimulating muscle growth in undernourished or underdeveloped patients. The drug was approved for human use by the [[Food and Drug Administration|FDA]]. However, later non-[[steroid]]al drugs such as [[Epogen]] were developed and proven to be more effective as a treatment for anaemia and osteoporosis without the side-effects of oxymetholone. The drug remained available despite this, and eventually found a new use in treating [[HIV|HIV wasting syndrome]]. While classified as a [[Controlled Substances Act#Schedule III drugs|Schedule III drug]] under the [[Controlled Substances Act]], it remains available via prescription as Anadrol®-50. Anadrol®-50 is a registered trademark of Alaven™ Pharmaceutical.  
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
|contraindications=* Condition1
 
<!--Warnings-->
|warnings=* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGender=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
|useInRace=There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
|useInRenalImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
|useInHepaticImpair=There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
|useInReproPotential=There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
|useInImmunocomp=There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
|administration=* Oral
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
|overdose====Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|mechAction=*
 
<!--Structure-->
|structure=*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
|PK=There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
|nonClinToxic=There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->
|clinicalStudies=There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
 
<!--How Supplied-->
|howSupplied=*
|packLabel=<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
 
<!--Precautions with Alcohol-->
|alcohol=* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title =  | url =  }}</ref>


Presented most commonly as a 50 [[milligram|mg]] [[tablet]], Oxymetholone is the strongest [[androgen]]ic steroid available. Similarly, it also poses the greatest risk of [[Adverse drug reaction|side effects]] of any steroid.
<!--Look-Alike Drug Names-->
Despite very low binding affinity with the [[androgen receptor]], oxymetholone is highly effective in promoting extensive gains in body mass, mostly by greatly improving protein synthesis. For this reason, it is often used illegally by bodybuilders and athletes. Many athletes also use Oxymetholone as a method of protection for the joints under heavy loads. Due to the high [[water retention]] users experience from this drug, it similarly lubricates the joints and helps protect them from injury. Oxymetholone is widely considered by bodybuilders to have the strongest anabolic effect out of any oral steroid available; weight increases of 20 pounds in 2 weeks are not unheard of with this drug.
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher = | date = }}</ref>


==Side effects==
<!--Drug Shortage Status-->
|drugShortage=
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->


The side-effects of short-term use of the drug itself include [[nausea]], [[bloating]], [[Acne vulgaris|acne]], and masculinising effects such as deepening of the voice, growth of facial hair and [[clitoral hypertrophy]] . In addition, oxymetholone is readily aromatized by [[aromatase]] to form a [[progestagen]], and unless [[selective estrogen receptor modulator]]s such as [[tamoxifen]] or [[clomifene]] are taken in conjunction with the drug, there is a significant risk of the appearance of [[estrogenic]] effects such as [[gynaecomastia]] over time. Because of its 17α-alkylated structure, oxymetholone is highly [[hepatotoxic]]. Long term use of the drug can cause a variety of serious ailments, including [[hepatitis]], [[liver cancer]], and [[cirrhosis]]. It's dangerous to take oxymetholone in high dosages for periods of time exceeding four weeks, and is commonly used by [[bodybuilders]] during the start of a [[steroid cycle]] to help gain mass and increase serum levels of [[androgens]] quickly.


==Use with other steroids==


To further increase its effectiveness as an anabolic agent, bodybuilders typically ''stack'' (see [[steroid stack]]) oxymetholone with other [[anabolic steroids]]. Since it is already a very potent [[androgen]], many users will combine it with drugs such as [[nandrolone]], [[boldenone]] and [[testosterone]] to further their gains.
<!--Label Display Image-->


==References==
<div class="references-small">
{{reflist|2}}
</div>


==External links==
*[http://www.anadrol.co.uk Information about Oxymetholone/Anadrol used as an anabolic steroid]
*[http://www.rxlist.com/cgi/generic3/oxymet.htm Oxymetholone information at Rxlist.com]




{{Anabolic steroids}}
[[Category:Anabolic steroids]]
[[Category:Endocrinology]]


[[fr:Oxymétholone]]
<!--Category-->
[[pt:Oximetolona]]


{{WikiDoc Help Menu}}
[[Category:Drug]]
{{WikiDoc Sources}}

Revision as of 17:19, 22 January 2015

Oxymetholone
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content

Overview

Oxymetholone is a {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Oxymetholone in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Oxymetholone in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Oxymetholone in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Oxymetholone in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Oxymetholone in pediatric patients.

Contraindications

  • Condition1

Warnings

ConditionName:
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Oxymetholone in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Oxymetholone in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Oxymetholone in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Oxymetholone during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Oxymetholone with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Oxymetholone with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Oxymetholone with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Oxymetholone with respect to specific gender populations.

Race

There is no FDA guidance on the use of Oxymetholone with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Oxymetholone in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Oxymetholone in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Oxymetholone in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Oxymetholone in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Oxymetholone in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Oxymetholone in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Oxymetholone in the drug label.

Pharmacology

There is limited information regarding Oxymetholone Pharmacology in the drug label.

Mechanism of Action

Structure

File:Oxymetholone01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Oxymetholone in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Oxymetholone in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Oxymetholone in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Oxymetholone in the drug label.

How Supplied

Storage

There is limited information regarding Oxymetholone Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Oxymetholone |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Oxymetholone |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Oxymetholone in the drug label.

Precautions with Alcohol

  • Alcohol-Oxymetholone interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. Empty citation (help)
  2. "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Oxymetholone
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Oxymetholone
 |Label Name=Oxymetholone11.png

}}

{{#subobject:

 |Label Page=Oxymetholone
 |Label Name=Oxymetholone11.png

}}